Ankylosing Spondyloarthritis clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.
San Francisco, California and other locations